Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer

Importance: Metastatic breast cancer with central nervous system (CNS) metastases carries a poor prognosis. Recently, CDK4/6 inhibitors have demonstrated a progression free survival (PFS) and overall survival benefit when combined with standard endocrine therapy in advanced hormone receptor (HR)+/HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Long V., Searle, Karlee, Jerzak, Katarzyna J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824870/
https://www.ncbi.nlm.nih.gov/pubmed/31695840
http://dx.doi.org/10.18632/oncotarget.27238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824870/
https://www.ncbi.nlm.nih.gov/pubmed/31695840
http://dx.doi.org/10.18632/oncotarget.27238

Ejemplares similares